10/19/2005 5:13:17 PM
COSTA MESA, Calif.--(BUSINESS WIRE)--Oct. 4, 2005--Valeant Pharmaceuticals International (NYSE:VRX) today announced that the company received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zelapar(TM) (selegiline hydrochloride). The approvable letter requests additional clarification on specific issues previously addressed by Valeant. Valeant plans to meet with the FDA, promptly as they have requested, to discuss and resolve these matters.
comments powered by